Alert: Canvas Outage Update
Canvas access has been restored for our users, but the service reliability remains uncertain. Due to recent events, Canvas has had intermittent outages which are at the discretion of the vendor and may occur during a final exam. Faculty and staff may continue to use Canvas, but we strongly advise faculty and students to prepare a contingency plan for turning in assignments and final exams in the event Canvas access becomes unavailable again.
Instructure, the company that owns Canvas, has provided an FAQ about the incident, which may not answer all your questions. We will share more information if it becomes available.
Instructure, the company that owns Canvas, has provided an FAQ about the incident, which may not answer all your questions. We will share more information if it becomes available.
Learn More
Department of Medicine Event Details
Review of 2019 American Society of Hematology Annual Meeting
|
07:30 AM - 02:30 PM
Denver Museum of Nature and Science
2001 Colorado Blvd
Denver, Colorado, 80205
Experts in lymphomas, plasma cell disorders, myeloproliferative neoplasms, acute myeloid leukemia, myelodysplastic syndrome, and coagulation disorders will provide exciting updates from ASH 2019 with a focus on the latest treatment advances relevant to your clinical practice. The day will include presentations, case reviews, and interactive question and answer sessions.
By the end of the review, attendees will be better equipped to: Identify which patients with hematologic malignancy may benefit from specific targeted therapies. Recognize myriad of presentations of patients with hematologic malignancy. Identify higher risk patients with hematologic malignancy and know best available therapies for these patients. Recognize best current approach to patients requiring more aggressive treatments. Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers). Manage complications of hematologic malignancies in an outpatient setting.
By the end of the review, attendees will be better equipped to: Identify which patients with hematologic malignancy may benefit from specific targeted therapies. Recognize myriad of presentations of patients with hematologic malignancy. Identify higher risk patients with hematologic malignancy and know best available therapies for these patients. Recognize best current approach to patients requiring more aggressive treatments. Prescribe individualized plans for patients with hematologic malignancies based on specific disease characteristics (genetics, molecular markers). Manage complications of hematologic malignancies in an outpatient setting.
Add event to: